What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients? Authors: Maéva Zysman, Fanchon Herman, Léo Grassion, Camille Taillé, Jesus Gonzalez-Bermejo, Marina Guecamburu, Nicolas Roche, Arthur Pavot, Pierre-Olivier Girodet, Arnaud Bourdin, Nicolas Molinari, Patrick Berger, on behalf of the COBRA Study Group Published: 2024 ABSTRACT AbstractIntroductionBiologics provide significant benefits in asthma, reducing exacerbations and symptoms. Some biologics have shown promising results in small subgroups of patients with chronic obstructive pulmonary disease (COPD) and frequent exacerbations. Nevertheless, real-life data on the size of the COPD target population remain scarce.MethodsWe analysed the characteristics of COPD and coexisting asthma and COPD patients included in the prospective multicentre, French COhort of BRonchial obstruction and Asthma, between 2008 and 2023 and evaluated the number of patients who could correspond to the inclusion criteria of randomised controlled trials evaluating various biologics targeting interleukin 33 (IL-33) (-receptor), IL-5 (-receptor), IL-4Rα or TSLP, in routine clinical practice.ResultsAmong 434 COPD patients, only 21.7% met inclusion criteria for at least one biologic. Among patients with asthma, 54 (3.5%) had coexisting features of COPD in terms of age, smoking status and airflow obstruction and met inclusion criteria for at least one biologic. Notably, these patients were predominantly female, with worse lung function. Globally, the target chronic airway diseases population of the eagerly awaited biologics remains limited to a small part (ie, 1.3%–8%, depending on the biologic).ConclusionIn a real-life COPD and asthma population (including asthmatic patients with features of COPD), the proportion of patients satisfying selection criteria applied in randomised controlled trials assessing the efficacy of biologics remains limited to less than 10% of the whole population.Keywords: COPD Pharmacology, Asthma Pharmacology, Eosinophil Biology, Asthma in primary care WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS Target COPD and asthma-COPD overlap patients for biologics corresponds to less than 10% of a real-life population. Target COPD and asthma-COPD overlap patients for biologics corresponds to less than 10% of a real-life population. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Real-world data suggest that only a limited proportion of patients with COPD would be eligible to enter clinical trials on biologics, emphasising the need to study broader patient populations to determine if personalise management using these agents could be extended. Real-world data suggest that only a limited proportion of patients with COPD would be eligible to enter clinical trials on biologics, emphasising the need to study broader patient populations to determine if personalise management using these agents could be extended. Introduction Biomarker-guided use of biologics targeting type 2 inflammation has been shown to provide significant benefits in asthma,1 reducing exacerbations and symptoms.2 In chronic obstructive pulmonary disease (COPD), however, blocking interleukin 5 (IL-5) or its receptor, using either mepolizumab or benralizumab, has failed to provide any significant reduction in acute exacerbations although some efficacy might be present in subgroups of patients with exacerbations and higher blood eosinophil counts.3 4 Besides, patients with coexisting asthma and COPD who have clinical features of both diseases may represent around 25% of COPD patients2 hence could become an important target for biologics. More recently, the BOREAS and the NOTUS studies evaluated the efficacy and safety of dupilumab, which blocks the IL-4 receptor alpha and thus the effects of both IL-4 and IL-13.5 6 939 COPD patients with a blood eosinophil count of at least 0.3×109/L, symptoms of chronic bronchitis and frequent exacerbations despite optimised inhaled therapy were included. A 30% reduction in the annual rate of moderate or severe exacerbations was observed in the dupilumab group (0.78 vs 1.10 exacerbation/year).5 Nevertheless, type 2 inflammation only affects 10%–40% of COPD patients7 and may vary over time,8 underlining the need for other biologics targeting other inflammatory pathways. New biologics targeting alarmins (ie, IL-33, TSLP) may fill this gap and promising results have been reported among COPD patients (especially ex- rather than current smokers) with frequent exacerbations (at least two moderate exacerbations or one severe exacerbation in the previous year), respiratory symptoms (CAT score ≥10) or chronic bronchitis despite dual or triple inhaled therapy.9 10 Altogether, several studies are currently evaluating the efficacy and safety of these various new agents. Awaiting their results, it appears important to delineate the corresponding potential target populations in a real-life chronic airway diseases population. Along this line, our aim was to assess the proportion of real-life COPD patients who would be eligible for the currently studied biologics according to inclusion criteria from randomised controlled trials. Methods For this purpose, we analysed the characteristics of the whole COPD and asthmatic patients included in the prospective multicentre, observational French COhort of BRonchial obstruction and Asthma (COBRA) sponsored by INSERM, between 2008 and 2023.11 COPD and asthma were physician diagnosed disease according to GOLD and GINA criteria, respectively. Patient and public involvement No patient involved. We evaluated the number of patients who could correspond to the inclusion criteria of studies evaluating the following biologics in COPD: astegolimab (anti-IL-33 receptor ST2, NCT05037929), benralizumab (anti IL-5-receptor, NCT04053634), dupilumab (anti-IL-4Rα, NCT03930732 and NCT04456673), itepekimab (anti-IL-33, NCT05326412) mepolizumab (anti-IL-5, NCT04133909), tezepelumab (anti-TSLP, NCT04039113), tozorakimab (anti IL-33, NCT05166889, NCT05158387 and NCT06040086), summarised in online supplemental table 1. Briefly, all patients should be at least 40 years old, with an airflow obstruction defined by forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7 and have experienced at least two moderate exacerbations or one severe exacerbation in the past year despite maximal inhaled therapy (dual or triple therapy). All patients were former or current smokers with a tobacco history of at least 10 pack-years at the inclusion. In addition to COPD patients, we considered that patients satisfying these criteria in the asthma population could be considered as asthma-COPD overlap, sharing with COPD the ‘fixed airflow obstruction treatable traits’. Of note, blood eosinophil counts higher than 0.3×109/L at least once during follow-up was sufficient to consider that a patient would meet this criterion when required. Results Among the 1949 patients included in the whole COBRA cohort, 434 patients were diagnosed as COPD (36.2% women, mean age: 63.4±9.9 years, FEV1 56±46%pred, 1.1±3.1 exacerbations/year, mean blood eosinophils/mm3: 275±793) and 1515 were diagnosed as asthmatics (63.6% women, mean age: 49.3±15.4 years, FEV1 80±30%pred, 1.2±1.1 exacerbations/year, mean blood eosinophils/mm3: 253±322, table 1). Table 1Patients’ characteristics of COPD, asthma and whole populations in the COBRA cohortCOPD populationN=434Asthma populationN=1515Whole COBRA cohortN=1949Gender (men, %)63.836.442.48Age (years±SD)63.4±9.949.3±15.452.5±15.5Smoking (pack-year±SD)52.6±49.15.9±21.816.1±35.7On triple or dual therapy (yes, %)78.183.882.5OLT (yes, %)26.630–mMRC score (mean±SD)2.71±1.28Not available–CAT score (mean±SD)18.7±7.1Not available–Chronic bronchitis (yes, %)Not available3.26–FEV1 (%pred±SD)56±4680±3075±36≥1 exacerbation in preceding year (%)43.844.444.3≥2 exacerbations in preceding year (%)21.67Not available–Eosinophil count (×109/L)0.27 (0.19, 0.36)0.25 (0.10, 0.40)0.26 (0.11, 0.38)Patients with eosinophils blood count ≥0.3×109/L9.4520.1317.75COBRACOhort of BRonchial obstruction and AsthmaCOPDchronic obstructive pulmonary diseaseFEV1forced expiratory volume in 1 sLTOTlong term oxygen therapymMRCmodified Medical Research Council Patients’ characteristics of COPD, asthma and whole populations in the COBRA cohort COBRACOhort of BRonchial obstruction and AsthmaCOPDchronic obstructive pulmonary diseaseFEV1forced expiratory volume in 1 sLTOTlong term oxygen therapymMRCmodified Medical Research Council Respectively, 94 (21.7 %) COPD (figure 1) and 54 (3.5%) asthmatic (figure 2) patients met the main inclusion criteria for trials of biologics in COPD (based on FEV1/FVC<0.7, smoking, inhaled treatment, number of exacerbations and age) for at least one biologic study (online supplemental table 1). These patients were significantly more frequently female and had a lower FEV1. From these patients, 28 (6.5%) COPD (figure 1) and 29 (1.9%) coexisting asthma and COPD (figure 2) had blood eosinophil counts higher than 0.3×109/L and may be eligible to biologics such as benralizumab, mepolizumab and/or dupilumab) (figure 1). Considering the whole population, 109 (5.6%) may be eligible to astegolimab, 38 (1.9%) to benralizumab, 26 (1.3%) to dupilumab, 91 (4.6%) to itepekimab, 38 (1.9%) to mepolizumab, 115 (5.9%) to tezepelumab and 148 (7.6%) to tozorakimab. Of note, 28 patients (1.4%) could be eligible only to tozorakimab, whereas only 24 (1.2%) could be eligible to all biologics (figures1 2). Flow chart for COPD patients from COhort of BRonchial obstruction and Asthma and Venn diagram corresponding to the inclusion criteria of studies evaluating the following biologics: astegolimab (anti-IL-33 receptor ST2, clinical trial NCT05037929), benralizumab (anti IL-5-receptor, NCT04053634), dupilumab (anti-IL-4Rα, NCT03930732), itepekimab (anti-IL-33, NCT05326412) mepolizumab (anti-IL-5, NCT04133909), tezepelumab (anti-TSLP, NCT04039113), tozorakimab (anti IL-33, NCT05166889 and NCT05158387). COPD, chronic obstructive pulmonary disease; IL, interleukin. Flow chart for asthma-COPD overlap patients from COhort of BRonchial obstruction and Asthma and Venn diagram corresponding to the inclusion criteria of studies evaluating the following biologics: astegolimab (anti-IL-33 receptor ST2, clinical trial NCT05037929), benralizumab (anti IL-5-receptor, NCT04053634), dupilumab (anti-IL-4Rα, NCT03930732), itepekimab (anti-IL-33, NCT05326412) mepolizumab (anti-IL-5, NCT04133909), tezepelumab (anti-TSLP, NCT04039113), tozorakimab (anti IL-33, NCT05166889 and NCT05158387). COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IL, interleukin. Discussion To the best of our knowledge, the present study is the first to evaluate the proportion of COPD and asthma-COPD overlap patients that may be eligible to biologics, in clinical practice. COBRA is a national cohort with centres from tertiary care only. The relatively small number of patients and more specifically of subjects with blood eosinophil count ≥0.3×109/L may limit the generalisability of our results. However, the proportion of ‘eosinophilic’ patients with COPD has been reported to range from 5% to 40%.12 Besides, included patients correspond to a broad range of lung function and clinical severity, with relatively low proportions of patients with FEV1 below 30%pred (76 (20%) from COPD and 14 (0.9%) from asthmatic patients), one severe or two moderate exacerbations in the previous year (91 (18.1%) and 61 (14.7%) patients, respectively). Indeed, even if the number of patients is low, the proportion of patients with frequent exacerbations were similar to those previously described in other cohorts.13 So, we do believe that the patients from COBRA represent a snapshot of real-life clinical practice in many industrial countries. The relatively low percentage of COPD patients eligible for new biologics deserves some comments. First, the situation is roughly comparable in asthma, where the percentage of patients eligible to biologics is also very low,14 since these agents are restricted to severe asthma which represents less than 5% of the whole asthmatic population.2 Similarly, in COPD, frequent exacerbations despite optimised inhaled therapy affect only a minority of patients.15 16 Second, while one would welcome new disruptive ‘universal’ treatments capable of dramatically improving the status of all patients with COPD or asthma-COPD overlap, for now the new agents to come target very specific populations. The main challenge is not to miss this specific population, which underlines the need to regularly assess patients and, when the situation is ‘uncontrolled’, to confront their needs and characteristics to the indications of new targeted therapies. It seems then crucial to periodically assess the likelihood and the representativeness of patients included in randomised controlled trials compared with daily practice patients. Last but not least, efficacy data are not yet available for all drugs discussed in this study, and the upcoming results of phase 3 studies will address these points. Besides, a negative clinical trial could be either related to the lack of efficacy of the drug or to the study design, notably the choice of inclusion criteria and primary outcomes. For example, first results of mepolizumab in asthma have been disappointing as participants did not have severe disease or eosinophilic airway inflammation.17 However, data from one first phase 3 trial has revealed encouraging results regarding dupilumab,5 and although preliminary, some data from phase 2 studies seem promising.9 10 Conclusion The target chronic airway diseases population of the eagerly awaited biologics remains limited to a small part (ie, 1.3%–8%). Despite the high prevalence of COPD and asthma, its significant morbidity and mortality, therapeutic resources remain very limited. Recent results may pave the way to biologics in the management of a subtype of exacerbating chronic airway diseases patients. However, we must keep in mind that the small number of eligible patients at this time required extensive research in chronic airway diseases to identify new disruptive and effective targets. supplementary material Footnotes Funding: COBRA is funded by Astra Zeneca, Glaxo-Smith Kline, Sanofi and Chiesi. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained directly from patient(s). Ethics approval: COBRA was approved by the Ethics Committee (CPP Ile de France 0811738) and written informed consent was obtained for all participants at inclusion. The study was designed according to the STROBE guidelines. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Contributor Information Maéva Zysman, Email: maeva.zysman@chu-bordeaux.fr. Fanchon Herman, Email: fanchon.herman@chu-montpellier.fr. Léo Grassion, Email: leo.grassion@chu-bordeaux.fr. Camille Taillé, Email: camille.taille@aphp.fr. Jesus Gonzalez-Bermejo, Email: jesus.gonzalez@aphp.fr. Marina Guecamburu, Email: marina.guecamburu@live.fr. Nicolas Roche, Email: nicolas.roche@aphp.fr. Arthur Pavot, Email: pavot.arthur@gmail.com. Pierre-Olivier Girodet, Email: pierre-olivier.girodet@chu-bordeaux.fr. Arnaud Bourdin, Email: a-bourdin@chu.montpellier. Nicolas Molinari, Email: n-molinari@chu-montpellier.fr. Patrick Berger, Email: patrick.berger@u-bordeaux.fr. Data availability statement Data are available upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available upon reasonable request.